v3.22.2.2
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Total net revenue $ 128,782 $ 121,340 $ 371,023 $ 358,597
COST OF REVENUE 79,889 74,101 239,952 216,794
GROSS PROFIT 48,893 47,239 131,071 141,803
Operating expenses:        
General and administrative 64,282 63,839 188,481 158,953
Research and development 7,312 7,409 23,651 13,360
Sales and marketing 16,809 15,704 50,179 46,677
Total operating expenses 88,403 86,952 262,311 218,990
Loss from operations (39,510) (39,713) (131,240) (77,187)
Interest expense, net 139 1,296 2,366 3,375
Other (income) expense, net (25) (89) 212 (431)
Gain on investment in and loan receivable from non-consolidated affiliate, net 0 (17,750) 0 (109,260)
(Loss) income before taxes (39,624) (23,170) (133,818) 29,129
Income tax benefit (2,772) (2,822) (12,255) (4,283)
NET (LOSS) INCOME $ (36,852) $ (20,348) $ (121,563) $ 33,412
NET (LOSS) INCOME PER SHARE        
Basic (in dollars per share) $ (0.30) $ (0.17) $ (0.98) $ 0.28
Diluted (in dollars per share) $ (0.30) $ (0.17) $ (0.98) $ 0.28
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING        
Basic (in shares) 124,425 122,559 124,055 119,087
Diluted (in shares) 124,425 122,559 124,055 121,356
Clinical Services        
Total net revenue $ 106,162 $ 102,227 $ 310,588 $ 300,119
COST OF REVENUE 65,261 59,560 197,563 178,358
GROSS PROFIT 40,901 42,667 113,025 121,761
Pharma Services        
Total net revenue 22,620 19,113 60,435 58,478
COST OF REVENUE 14,628 14,541 42,389 38,436
GROSS PROFIT $ 7,992 $ 4,572 $ 18,046 $ 20,042

Source